top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

Updated: Mar 20

13/03/2026











Immutep's Phase 3 TACTI-004 trial of eftilagimod alfa regimen in 1L NSCLC NSCLC has been discontinued (Ref)


Based on the Independent Data Monitoring Committee (IDMC) recommendation, Immutep's Phase 3 TACTI-004 trial of eftilagimod alfa (LAG-3 MHC Class II agonist) + pembrolizumab + chemo regimen as a first-line treatment of NSCLC has been discontinued.


  • Following a planned interim futility analysis in accordance with the study protocol, the IDMC recommended that the trial be discontinued for futility


  • The enrolment in the study will be halted and the company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations




Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page